retatrutide weight loss trial UK 2026: Phase 3 Results Retatrutide (“reta”) is an experimental

Fontana L, Partridge L, Longo VD

Origin and Development of Retatrutide Creating treatments for obesity has been tough because of side effects and limited results

At week 72, the clinical data showed that 36.8% of patients receiving semaglutide achieved fibrosis improvement without worsening of NASH and 62.9% achieved NASH resolution without worsening of fibrosis, compared with 22.4% and 34.3%, respectively, in the placebo group (Sanyal et al., 2025)

Seek urgent medical attention for severe difficulty breathing, inability to swallow, or progressive dysphagia whilst taking Saxenda

You can help optimize how medications like semaglutide work by doing regular physical activity and following a healthy diet

As GLP-1s surge in popularity, are your healthcare clients prepared for the new risks these medications introduce